Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
135 hedge funds and large institutions have $343M invested in Progenics Pharmaceuticals Inc in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 49 increasing their positions, 44 reducing their positions, and 16 closing their positions.
128% more call options, than puts
Call options by funds: $2.26M | Put options by funds: $993K
11% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 44
5% less funds holding
Funds holding: 142 → 135 (-7)
17% less capital invested
Capital invested by funds: $415M → $343M (-$72M)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.5M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.01M |
| 3 |
BC
Broadfin Capital
New York
|
+$7.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$946K |
| 5 |
Citigroup
New York
|
+$573K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.19M |
| 3 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$4.01M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
-$2.75M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.58M |
PGNX Hedge Fund Activity: Q3 2019 in Review
135 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2019, worth a combined $343M — down 17% from $415M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PGNX and 10 opened new positions — a net loss of 6 holders — while 44 trimmed existing stakes and 49 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $18.5M. The largest seller was Point72 Asset Management, cutting an estimated $15.3M.
- 135 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2019, down from 142 in Q2 2019.
- Funds reported $343M of Progenics Pharmaceuticals Inc stock for Q3 2019, down 17% quarter-over-quarter.
- 10 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2019 and 16 closed out, a net change of -6 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q3 2019 was T. Rowe Price Associates, an estimated $18.5M added.
- The largest Progenics Pharmaceuticals Inc seller in Q3 2019 was Point72 Asset Management, an estimated $15.3M sold.
Based on aggregated 13F filings for Q3 2019.